i2o Therapeutics
Allston
About i2o Therapeutics
i2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies traditionally limited to injections. Using an innovative ionic liquid technology, it leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally. i2o is focused on creating the next generation of oral peptide and protein-based therapies. The company was founded in 2019 and based in Saratoga, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $90.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2023)
- Website: i2obio.com
- Phone: 408-476-1904
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/i2o-therapeutics-89851 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.